Effects of Clinical Pilates Exercises on Symptoms, Posture, Balance and Quality of Life in GERD
The Effect of Clinical Pilates Exercises on Symptoms, Posture, Balance and Quality of Life in Individuals With Gastroesophageal Reflux Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Istanbul, Turkey (Türkiye)
- Istinye University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-65 years.
- Clinically confirmed diagnosis of gastroesophageal reflux disease (GERD).
- Self-reported GERD symptoms (heartburn, acid regurgitation, etc.) for at least 3 months prior to enrollment.
- Physiologically able to participate in low-to-moderate intensity exercise.
- Provision of written informed consent.
- Cognitive and psychosocial capacity to comply with the program.
Exclusion Criteria:
- History of upper gastrointestinal surgery (especially fundoplication).
- Achalasia or severe esophageal motility disorder.
- Endoscopic evidence of advanced esophagitis, Barrett's esophagus, or esophageal stricture (complicated GERD).
- Active peptic ulcer disease or inflammatory bowel disease.
- Uncontrolled hypertension, coronary artery disease, or severe pulmonary disease.
- Severe musculoskeletal disorders (advanced scoliosis/kyphosis, acute disc herniation, severe osteoarthritis) or vestibular balance disorders.
- Pregnancy or suspected pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: No Intervention: Control Group (CG)
Participants continued their routine daily activities without any structured exercise intervention for the 6-week study period.
Outcome measurements were performed at baseline and at week 6 using identical procedures and instruments as the Pilates group.
|
No supervised exercise; participants were instructed to maintain their usual physical activity pattern and lifestyle for 6 weeks.
They received the same baseline and week-6 assessments as the experimental group.
|
|
Experimental: Experimental: Clinical Pilates Group (PG)
Posture-focused clinical Pilates exercise program tailored for individuals with GERD.
All exercises were performed in the standing position, avoiding anterior trunk flexion and direct abdominal compression to minimize intra-abdominal pressure.
Sessions were held 3 times/week for 6 weeks (18 supervised face-to-face sessions).
Each session contained a ~10-minute warm-up, a main phase of standing posture/balance Pilates exercises, and a 5-10-minute cool-down/stretching phase.
|
No supervised exercise; participants were instructed to maintain their usual physical activity pattern and lifestyle for 6 weeks.
They received the same baseline and week-6 assessments as the experimental group.
18 face-to-face sessions over 6 weeks (3×/week); physiotherapist-led, posture-focused program performed exclusively in the standing position.
Warm-up/cool-down: Cleopatra, upper-extremity PNF patterns, Toy Soldier, Corkscrew, Chest Stretch (10 reps each).
Main phase: Tic-Toc Arm Float, Bow & Arrow, Spine Twist, Footwork, Knee Lift & Aeroplane, Plié - Second to First - Moving Balance, Balance, Balance Plié with Arms.
Progression by repetitions (5 → 10) and active duration (5 s → 10 s → 15 s); one set per exercise; 30-second rest between sets.
Sessions were timed at least 2 hours after meals or at least 30 minutes before eating to limit gastric distension.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gastroesophageal Reflux Disease Questionnaire (GERD-Q) total score
Time Frame: Baseline to Week 6
|
Six-item self-report instrument measuring frequency of typical reflux symptoms over the past week; total score range 0-18, with higher scores indicating greater symptom burden and a cut-off of ≥8 suggesting high probability of GERD.
Safety Issue: No.
|
Baseline to Week 6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency Scale for the Symptoms of GERD (FSSG) total score
Time Frame: Baseline to Week 6
|
Twelve-item self-report scale assessing the frequency of acid-reflux and dyspeptic symptoms; total score range 0-48, with higher scores indicating more frequent symptoms (≥8 considered positive for GERD).
Safety Issue: No.
|
Baseline to Week 6
|
|
Short Form-36 Health Survey (SF-36) total score
Time Frame: Baseline to Week 6
|
36-item generic health-related quality-of-life questionnaire covering eight domains (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health); each domain and the total score scaled 0-100, higher scores reflecting better health-related quality of life.
Safety Issue: No.
|
Baseline to Week 6
|
|
Pittsburgh Sleep Quality Index (PSQI) global score
Time Frame: Baseline to Week 6
|
19-item self-report instrument generating a global score from seven components (subjective sleep quality, latency, duration, efficiency, disturbances, medication use, daytime dysfunction); global score 0-21, with higher scores indicating poorer sleep quality (≥5 indicates poor sleep).
Safety Issue: No.
|
Baseline to Week 6
|
|
Beck Depression Inventory (BDI) total score
Time Frame: Baseline to Week 6
|
21-item self-report inventory assessing severity of depressive symptoms over the past week; total score 0-63, with higher scores indicating greater depressive symptom severity.
Safety Issue: No.
|
Baseline to Week 6
|
|
Postural Alignment Parameters (PostureScreen Mobile)
Time Frame: Baseline to Week 6
|
Photographic postural assessment performed in anterior, posterior, right and left lateral standing views using the PostureScreen Mobile application.
Outcomes include sagittal anterior translations and posterior translations of head, shoulder, thorax, pelvis, and segmental spinal translations (T1-T4, T4-T8, T8-T12, T12-L3, L3-SIPS); frontal lateral translations of head, shoulder, pelvis, and knee.
Values reported in cm and degrees; values closer to zero indicate better postural alignment.
Safety Issue: No.
|
Baseline to Week 6
|
|
Y-Balance Test reach distances
Time Frame: Baseline to Week 6
|
Dynamic balance assessment in which participants reach as far as possible in three directions (anterior, posteromedial, posterolateral) on each lower limb while maintaining single-leg stance.
Maximum reach distance is recorded in centimeters bilaterally; greater reach distances reflect better dynamic balance and lower-limb neuromuscular control.
Safety Issue: No.
|
Baseline to Week 6
|
|
Anthropometric circumference measurements
Time Frame: Baseline to Week 6
|
Tape-measure assessment of chest circumference, sub-sternal (sub-xiphoid) circumference, and waist circumference, recorded in centimeters using standardized landmarks at end-tidal expiration.
Safety Issue: No.
|
Baseline to Week 6
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GERD-P 25-29
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.